AOD-9604 vs Semaglutide
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: Anti-Obesity Drug 9604, Tyr-hGH Fragment 177-191
AOD-9604 is a synthetic fragment of human growth hormone, copying just the last 15 amino acids of the hormone (residues 176 to 191) plus a tyrosine cap. The idea was to keep the fat-burning end of growth hormone while leaving out the part that raises IGF-1 or messes with blood sugar. It was developed by Metabolic Pharmaceuticals in Australia and tested as an anti-obesity drug, but it is not approved by the FDA or any major regulator, and development stopped after it missed its weight-loss targets.
Also: Ozempic, Wegovy
Semaglutide is a GLP-1 receptor agonist, a peptide engineered to mimic the natural gut hormone GLP-1 but with a roughly week-long half-life so it can be dosed once weekly. It is FDA-approved and sold as Ozempic and Rybelsus for type 2 diabetes and as Wegovy for chronic weight management, with cardiovascular benefit also on the label. This is one of the most rigorously tested peptides in existence, backed by large randomized trials, so the evidence here is in a completely different league from research-only peptides.
Key Comparison Insights
- Semaglutide is FDA approved, while AOD-9604 remains in research stages.
- Both peptides belong to the Weight Loss category, suggesting similar primary applications.
- Semaglutide has stronger research evidence (FDA Approved) compared to AOD-9604 (Human Trials).
Detailed Comparison
| Attribute | AOD-9604 | Semaglutide |
|---|---|---|
| Category | Weight Loss | Weight Loss |
| FDA Status | Not FDA Approved | FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | In lab and animal studies, AOD-9604 appears to nudge fat cells toward breaking down stored fat (lipolysis) and away from making new fat (lipogenesis), echoing the lipolytic tail-end of the full growth hormone molecule. Unlike real growth hormone, it does this without meaningfully raising IGF-1, the downstream growth signal that drives growth hormone's anabolic and blood-sugar effects. The exact receptor it works through is not pinned down, and a clean, growth-hormone-receptor-independent pathway remains a working hypothesis rather than settled science. In short, the proposed selling point is fat-burning signaling without the classic growth hormone baggage, but the molecular details are still fuzzy. | Semaglutide latches onto the GLP-1 receptor, the same receptor your own GLP-1 hormone uses after a meal. Activating it tells the pancreas to release more insulin when blood sugar is high, dials down glucagon (the hormone that raises blood sugar), and slows how fast the stomach empties, so you feel full longer. It also acts on appetite centers in the hypothalamus, which is the main reason it reduces hunger and drives weight loss. The molecule was modified with a fatty-acid chain that binds to albumin in the blood, which is the trick that stretches its half-life to about 160 hours and allows once-weekly injection. |
| Common Dosing | 300 mcg daily Once daily, usually morning fasted | 1-2.4 mg weekly (after titration) Once weekly |
| Administration | Subcutaneous injection or oral (studied both) | Subcutaneous injection weekly, or oral (Rybelsus) |
| Typical Duration | 12-24 weeks in studies | Long-term / chronic use |
| Best Time to Take | Morning (fasted) | Morning, same day each week |
Possible Side Effects May vary by individual |
|
|
| Research Summary | The animal and cell data look encouraging, but the human story is where it falls apart. Across roughly six randomized, double-blind, placebo-controlled trials involving about 900 people, a safety review published in the Journal of Endocrinology and Metabolism (Moré et al.) found AOD-9604 was well tolerated, did not raise IGF-1, did not harm glucose metabolism, and triggered no detectable antibodies. The catch: it did not deliver clinically meaningful weight loss. The largest Phase IIb obesity trial failed to beat placebo on its main endpoint, and Metabolic Pharmaceuticals halted clinical development around 2007. So the honest summary is a peptide with a clean safety record in humans and essentially no proven efficacy for fat loss in humans. | The clinical evidence is extensive and high quality. The SUSTAIN program established blood-sugar control in type 2 diabetes, and SUSTAIN 6 showed a reduction in cardiovascular events. For obesity, the landmark STEP 1 trial (published in the New England Journal of Medicine in 2021) randomized nearly 2,000 adults without diabetes and found mean weight loss of 14.9% at 68 weeks on semaglutide 2.4 mg versus 2.4% on placebo, with most patients losing at least 5% of body weight. These are large, randomized, placebo-controlled trials, not pilot data. Common side effects are gastrointestinal (nausea, vomiting, constipation), usually worst during dose escalation. An oral version has also now been approved for weight loss. Unlike most peptides discussed in research circles, semaglutide is a fully approved medicine with a deep, published evidence base. |
Frequently Asked Questions: AOD-9604 vs Semaglutide
What is the difference between AOD-9604 and Semaglutide?
AOD-9604 is a weight loss peptide that aod-9604 is a synthetic fragment of human growth hormone, copying just the last 15 amino acids of the hormone (residues 176 to 191) plus a tyrosine cap. the idea was to keep the fat-burning end of growth hormone while leaving out the part that raises igf-1 or messes with blood sugar. it was developed by metabolic pharmaceuticals in australia and tested as an anti-obesity drug, but it is not approved by the fda or any major regulator, and development stopped after it missed its weight-loss targets. Semaglutide is a weight loss peptide that semaglutide is a glp-1 receptor agonist, a peptide engineered to mimic the natural gut hormone glp-1 but with a roughly week-long half-life so it can be dosed once weekly. it is fda-approved and sold as ozempic and rybelsus for type 2 diabetes and as wegovy for chronic weight management, with cardiovascular benefit also on the label. this is one of the most rigorously tested peptides in existence, backed by large randomized trials, so the evidence here is in a completely different league from research-only peptides. The main differences lie in their mechanisms of action and clinical applications.
Which is better, AOD-9604 or Semaglutide?
Neither is universally "better" - the choice depends on your specific goals. AOD-9604 is typically used for weight loss purposes, while Semaglutide is used for weight loss. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can AOD-9604 and Semaglutide be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using AOD-9604 and Semaglutide together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.